Urinary Tract Infection Treatment Guidelines

Introduction to UTI Treatment

The World Health Organization recommends trimethoprim-sulfamethoxazole as a first-line alternative for uncomplicated lower urinary tract infections in patients allergic to nitrofurantoin, provided local E. coli resistance rates are below 20% 1, 2
The WHO Expert Committee lists trimethoprim-sulfamethoxazole as a first-choice Access antibiotic, with evidence showing equivalence to fluoroquinolones and nitrofurantoin for both short-term and long-term symptomatic cure 1, 2

The American Academy of Pediatrics and the Infectious Diseases Society of America recommend amoxicillin-clavulanate as a first-line option for uncomplicated cystitis, particularly in pediatric populations aged 2-24 months 2, 5
The WHO Expert Committee retained amoxicillin-clavulanate as a guideline-endorsed first-line option based on generally high E. coli susceptibility rates in urinary isolates 3, 4
Check local resistance patterns before prescribing trimethoprim-sulfamethoxazole: If community E. coli resistance exceeds 20%, this agent should not be used empirically 6
Recent antibiotic exposure matters: trimethoprim-sulfamethoxazole use within the preceding 3-6 months is an independent risk factor for trimethoprim-sulfamethoxazole resistance 6
Recent travel history: Travel outside the United States in the preceding 3-6 months increases risk of trimethoprim-sulfamethoxazole resistance 6

The Infectious Diseases Society of America recommends ciprofloxacin as the first-choice option for mild-to-moderate pyelonephritis if local resistance rates allow its use (generally <10% resistance threshold) 3, 4
Ceftriaxone or cefotaxime are second-choice alternatives for mild-to-moderate pyelonephritis 3, 4
Ceftriaxone or cefotaxime are first-choice options for severe pyelonephritis 3, 4
Amikacin is the preferred aminoglycoside over gentamicin due to better resistance profiles and effectiveness against extended-spectrum β-lactamase-producing isolates 3, 4

For newborns and young infants, parenteral ampicillin plus an aminoglycoside OR ampicillin plus a third-generation cephalosporin are recommended 2, 5
For ages 3-24 months, oral amoxicillin-clavulanate or trimethoprim-sulfamethoxazole are recommended 2, 5
For children >6 months with uncomplicated pyelonephritis, a third-generation cephalosporin is recommended 2
Never use nitrofurantoin for febrile UTIs/pyelonephritis in children due to inadequate tissue penetration 5

Do not use plain amoxicillin: Global resistance data shows a median of 75% E. coli resistance (range 45-100%), leading to its removal from WHO recommendations in 2021 3, 4
Avoid empiric fluoroquinolones for simple cystitis: Reserve these for pyelonephritis or when other options are unsuitable due to resistance concerns and serious adverse effects 3, 4
Hospital antibiograms may mislead: These often reflect complicated infections and inpatient populations with higher resistance rates than community-acquired uncomplicated UTIs 6
Adjust therapy based on culture results: Clinical improvement should occur within 24-48 hours; use culture and sensitivity to guide definitive therapy 5